VICTORIA: Vericiguat Response and Outcomes by Index Heart Failure Event

November 13-17, 2020; Virtual Conference
Risk of CV death or hospitalization for HF was highest in patients with hospitalization for HF within 3 months prior to study.
Format: Microsoft PowerPoint (.ppt)
File Size: 217 KB
Released: November 18, 2020


Provided by Clinical Care Options

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from

Related Content

High-dose trivalent influenza vaccine comparable to standard-dose quadrivalent vaccine in deaths or cardiopulmonary hospitalizations in high-risk CV disease; AHA results reported by CCO

Released: November 20, 2020

Ferric carboxymaltose reduced risk of subsequent hospitalization in iron-deficient acute heart failure: AFFIRM-AHF data from AHA 2020, by CCO

Released: November 18, 2020

Omecamtiv mecarbil reduced time to first heart failure event or cardiovascular death in patients with heart failure with reduced ejection fraction: GALACTIC-HF data from AHA 2020 as reported by CCO

Released: November 16, 2020

CCO’s Expert insights from ACC.20/WCC: Akshay S. Desai, MD, MPH discusses recent findings from practice-changing heart failure studies

Akshay Suvas Desai, MD, MPH Released: April 17, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.